Dynavax Technologies Corporation (DVAX)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 27,309 | -6,389 | 293,156 | 76,713 | -91,776 |
| Total stockholders’ equity | US$ in thousands | 596,799 | 622,072 | 581,013 | 222,374 | 58,693 |
| ROE | 4.58% | -1.03% | 50.46% | 34.50% | -156.37% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $27,309K ÷ $596,799K
= 4.58%
Dynavax Technologies Corporation's return on equity (ROE) has displayed significant volatility over the past few years. The ROE was notably negative at -156.37% as of December 31, 2020, suggesting that the company was generating a net loss relative to its shareholders' equity during that period. However, the following years saw a reversal in performance, with ROE improving to 34.50% as of December 31, 2021, and further to 50.46% as of December 31, 2022, indicating a substantial increase in profitability and efficiency in utilizing equity to generate earnings.
Despite these positive trends, the company's ROE experienced negative performance again at -1.03% as of December 31, 2023, which could raise concerns about declining profitability or ineffective capital allocation. Nonetheless, there was a slight recovery in ROE to 4.58% as of December 31, 2024, although it remains relatively low compared to the peak in 2022.
Overall, Dynavax Technologies Corporation's ROE has shown mixed results over the years, reflecting fluctuations in financial performance and efficiency in utilizing shareholders' equity. Further analysis of the underlying factors driving these fluctuations would be necessary to assess the company's long-term sustainability and profitability.
Peer comparison
Dec 31, 2024